Targeting histone deacetylases for the treatment of Huntington's disease
- PMID: 20642797
- PMCID: PMC6493857
- DOI: 10.1111/j.1755-5949.2010.00184.x
Targeting histone deacetylases for the treatment of Huntington's disease
Abstract
Huntington's disease is a debilitating neurodegenerative condition with significant burdens on both patient and healthcare costs. Despite the identification of the causative element, an expanded toxic polyglutamine tract in the mutant Huntingtin protein, treatment options for patients with this disease remain limited. In the following review I assess the current evidence suggesting that a family of important regulatory proteins known as histone deacetylases may be an important therapeutic target in the treatment of this disease.
© 2010 Blackwell Publishing Ltd.
Conflict of interest statement
The authors have no conflict of interest.
Figures
Similar articles
-
Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).Curr Alzheimer Res. 2006 Sep;3(4):403-8. doi: 10.2174/156720506778249407. Curr Alzheimer Res. 2006. PMID: 17017871 Review.
-
[Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Feb;27(1):52-5. doi: 10.3760/cma.j.issn.1003-9406.2010.01.011. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010. PMID: 20140868 Review. Chinese.
-
Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.J Huntingtons Dis. 2015;4(1):1-15. doi: 10.3233/JHD-159001. J Huntingtons Dis. 2015. PMID: 25813218 Review.
-
Epigenetics of Huntington's Disease.Adv Exp Med Biol. 2017;978:277-299. doi: 10.1007/978-3-319-53889-1_15. Adv Exp Med Biol. 2017. PMID: 28523552 Review.
-
Epigenetic treatment of neurological disease.Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67. Epigenomics. 2011. PMID: 22126204 Review.
Cited by
-
Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4.Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):E3687-95. doi: 10.1073/pnas.1209990110. Epub 2012 Dec 10. Proc Natl Acad Sci U S A. 2012. PMID: 23236169 Free PMC article.
-
A double-edged sword with therapeutic potential: an updated role of autophagy in ischemic cerebral injury.CNS Neurosci Ther. 2012 Nov;18(11):879-86. doi: 10.1111/cns.12005. Epub 2012 Sep 24. CNS Neurosci Ther. 2012. PMID: 22998350 Free PMC article. Review.
-
Small non-coding RNAs add complexity to the RNA pathogenic mechanisms in trinucleotide repeat expansion diseases.Front Mol Neurosci. 2013 Dec 3;6:45. doi: 10.3389/fnmol.2013.00045. Front Mol Neurosci. 2013. PMID: 24348326 Free PMC article. Review.
-
Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm.Inflammopharmacology. 2024 Jun;32(3):1791-1804. doi: 10.1007/s10787-024-01477-0. Epub 2024 Apr 23. Inflammopharmacology. 2024. PMID: 38653938 Review.
-
Epigenetics and Metabolism in Health and Disease.Front Genet. 2018 Sep 18;9:361. doi: 10.3389/fgene.2018.00361. eCollection 2018. Front Genet. 2018. PMID: 30279699 Free PMC article.
References
-
- Walker FO. Huntington's disease. Lancet 2007;369:218–228. - PubMed
-
- DiFiglia M, Sapp E, Chase K, et al Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075–1081. - PubMed
-
- Group THsDCR . A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971–983. - PubMed
-
- Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin‐1 nuclear localization and aggregation: Role in polyglutamine‐induced disease in SCA1 transgenic mice. Cell 1998;95:41–53. - PubMed
-
- Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999;156:92–99. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical